Sunitinib and Capecitabine for First Line Colon Cancer

Inclusion Criteria: * Histologically confirmed, newly diagnosed metastatic colorectal cancer * Measurable or evaluable disease in which surgical resection with curative intent is not possible * No adjuvant chemotherapy within 6 months of enrollment * No prior sunitinib or other receptor tyrosine kinase inhibitors * 18 years of age or greater * Anticipated survival of at least 6 months * Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight * Normal organ and marrow function * Must agree to avoid pregnancy or fathering a child through out study participation * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Chemotherapy or radiotherapy within 6 months of enrollment * Receiving any other investigational agents * Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis * Not able to ingest oral medications with normal absorption from the GI tract * Uncontrolled hypertension * History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment * Cardiac dysrhythmias * History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment * Current treatment with therapeutic doses of coumadin * Concurrent malignancy other than colorectal cancer * Known dihydropyrimidine dehydrogenase deficiency * Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements. * Pregnant and nursing women